Crocodile Garments Limited (HKG:0122)
Hong Kong · Delayed Price · Currency is HKD 1.990
-0.070 (-3.40%)
At close: Jul 31, 2025
Ligand Pharmaceuticals Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | 2015 - 2019 |
| 97.15 | 95.33 | 86.88 | 103.29 | 112 | Upgrade | |
Revenue Growth (YoY) | 1.91% | 9.73% | -15.89% | -7.78% | -25.96% | Upgrade |
Cost of Revenue | 18.78 | 16.95 | 14.04 | 28.44 | 30.56 | Upgrade |
Gross Profit | 78.37 | 78.38 | 72.83 | 74.85 | 81.44 | Upgrade |
Selling, General & Admin | 99.2 | 100.94 | 94.82 | 96.14 | 92.05 | Upgrade |
Operating Expenses | 99.2 | 100.94 | 94.82 | 96.14 | 92.05 | Upgrade |
Operating Income | -20.83 | -22.56 | -21.98 | -21.29 | -10.61 | Upgrade |
Interest Expense | -44.52 | -46.39 | -36.55 | -11.1 | -11.53 | Upgrade |
Interest & Investment Income | 6.62 | 7.38 | 7.07 | 1.1 | 1.3 | Upgrade |
Earnings From Equity Investments | -0.72 | 0.16 | -1.68 | 1.9 | -1.17 | Upgrade |
Currency Exchange Gain (Loss) | 0.08 | 8.38 | 0.02 | 0.28 | -0.88 | Upgrade |
Other Non Operating Income (Expenses) | 17.5 | 10.91 | 8.85 | 17.68 | 11.8 | Upgrade |
EBT Excluding Unusual Items | -41.88 | -42.13 | -44.27 | -11.44 | -11.09 | Upgrade |
Gain (Loss) on Sale of Investments | 6.05 | 3.27 | 9.63 | -26.4 | 5.07 | Upgrade |
Gain (Loss) on Sale of Assets | 5.83 | 4.05 | 0.03 | -0.19 | 0.17 | Upgrade |
Asset Writedown | -19.38 | -19.01 | -75.24 | -47.59 | -7.97 | Upgrade |
Other Unusual Items | - | - | 0.21 | 7.24 | 11.88 | Upgrade |
Pretax Income | -49.39 | -53.81 | -109.64 | -78.39 | -1.93 | Upgrade |
Income Tax Expense | -14.17 | -19.97 | -0.85 | - | - | Upgrade |
Net Income | -35.22 | -33.84 | -108.79 | -78.39 | -1.93 | Upgrade |
Net Income to Common | -35.22 | -33.84 | -108.79 | -78.39 | -1.93 | Upgrade |
Shares Outstanding (Basic) | 71 | 71 | 65 | 47 | 47 | Upgrade |
Shares Outstanding (Diluted) | 71 | 71 | 65 | 47 | 47 | Upgrade |
Shares Change (YoY) | - | 8.57% | 38.16% | - | - | Upgrade |
EPS (Basic) | -0.50 | -0.48 | -1.66 | -1.65 | -0.04 | Upgrade |
EPS (Diluted) | -0.50 | -0.48 | -1.66 | -1.65 | -0.04 | Upgrade |
Free Cash Flow | -7.68 | - | 0.86 | -27.96 | 39.91 | Upgrade |
Free Cash Flow Per Share | -0.11 | - | 0.01 | -0.59 | 0.84 | Upgrade |
Gross Margin | 80.67% | 82.22% | 83.83% | 72.47% | 72.71% | Upgrade |
Operating Margin | -21.44% | -23.67% | -25.30% | -20.61% | -9.47% | Upgrade |
Profit Margin | -36.25% | -35.50% | -125.22% | -75.89% | -1.73% | Upgrade |
Free Cash Flow Margin | -7.91% | - | 1.00% | -27.07% | 35.64% | Upgrade |
EBITDA | -14.96 | -18.86 | -18.28 | -14.73 | -4.73 | Upgrade |
EBITDA Margin | -15.39% | -19.78% | -21.04% | -14.26% | -4.23% | Upgrade |
D&A For EBITDA | 5.88 | 3.7 | 3.7 | 6.56 | 5.88 | Upgrade |
EBIT | -20.83 | -22.56 | -21.98 | -21.29 | -10.61 | Upgrade |
EBIT Margin | -21.44% | -23.67% | -25.30% | -20.61% | -9.47% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.